Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Takes Stake in CardioDx; Forms MDx Alliance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare has invested $5 million in molecular diagnostics firm CardioDx as part of a Series D round of financing for the startup.

GE Healthcare also said that it has formed an alliance with the Palo Alto, Calif.-based firm to co-develop diagnostic technologies for the care and management of patients with cardiovascular disease.

CardioDx is developing a gene expression-based test, called Corus CAD, that is aimed at determining the likelihood that a patient has obstructive coronary artery disease. Such a test would enable physicians to determine a patient's status non-invasively, rather than through a combination of invasive and non-invasive methods.

The $5 million equity investment was made through the GE Healthymagination Fund, a $250 million fund which seeks to invest in firms developing technologies with the potential of reducing cost, increasing access, and improving quality in healthcare, said GE. The firms did not disclose the percentage of CardioDx equity that GE now owns.

"The alliance with CardioDx gives us access to new and exciting technologies in high-value diagnostics, which will complement and strengthen our existing offerings," Pascale Witz, president and CEO of GE Healthcare's Medical Diagnostics business, said in a statement. "CardioDx is an excellent strategic fit with GE Healthcare, given our common focus on cardiovascular disease."

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.